Anti-GPC-1 Antibodies for Therapeutic & Imaging Applications

Our patented antibodies target Glypican-1 (GPC-1), a protein significantly overexpressed in numerous solid tumor cancers such as prostate, pancreatic, bladder, glioblastoma, esophageal, lung, and ovarian. Notably, GPC-1 is not found in normal adult tissues.

Clinical Trials: We have successfully completed a First-in-Human trial in Australia using Miltuximab, our anti-GPC-1 monoclonal antibody (ANZCTR registry). The trial dosed 12 cancer patients and no drug-related adverse events were observed.

Upcoming Trials: We are currently raising funds for an Investigator Initiated Trial involving 16 additional patients. This trial will pave the way for our planned Phase-1b trial, utilizing PET imaging with ⁸⁹Zr-Miltuximab to select patients eligible for therapeutic treatment with ¹⁷⁷Lu-Miltuximab.

Research & Development: In addition to developing our Zirconium-89 and Lutetium-177 labelled molecules, we have an alpha program in collaborations with the University of Queensland ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) Furthermore, we are developing innovative novel chelators and chemistry at the Monash University ARC Training Centre for Radiochemical Technologies and Precision Radiopharmaceuticals (DART).

Antibody Humanization Program: Our Glytuzumab antibody is the humanized version of Miltuximab that also targets human GPC-1. The program is currently in Lead Optimization and Lead Selection stages. Several humanized leads with similar binding affinities to the parent molecule Miltuximab have been generated. The final selected Glytuzumab lead will proceed from cell line development to large-scale GMP production for future clinical trials.